Advertisement
Screener

Palvella Therapeutics, Inc. (PVLA) Material Contracts, 2016

Palvella Therapeutics, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2016-10-05: Form 8-K; Exhibit 10.1; Description Sales Agreement dated October 5, 2016 by and between Pieris Pharmaceuticals, Inc. and Cowen and Company, LLC.
  • 2016-08-11: Form 10-Q; Exhibit 10.1; Description Definitive License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. dated as of June 6, 2016..
  • 2016-07-20: Form 10-Q/A; Exhibit 10.1; Description License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. dated as of April 18, 2016..
  • 2016-07-20: Form 10-K/A; Exhibit 10.11; Description Research Collaboration and License Agreement by and among the Registrant, Pieris GmbH, Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd., dated as of December 8, 2015.
FiledFormExhibitDescription
2016-10-058-K10.1Sales Agreement dated October 5, 2016 by and between Pieris Pharmaceuticals, Inc. and Cowen and Company, LLC
2016-08-1110-Q10.1Definitive License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. dated as of June 6, 2016.
2016-07-2010-Q/A10.1License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc. dated as of April 18, 2016.
2016-07-2010-K/A10.11Research Collaboration and License Agreement by and among the Registrant, Pieris GmbH, Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd., dated as of December 8, 2015
2016-07-018-K10.1Pieris Pharmaceuticals, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan
2016-06-068-K10.3Registration Rights Agreement, dated June 2, 2016, by and among the Company and the Investors named therein
2016-06-068-K10.2Form of Warrant to purchase Common Stock
2016-06-068-K10.1Securities Purchase Agreement, dated June 2, 2016, by and among the Company and the Investors named therein
2016-05-1210-Q10.2Non-Employee Director Compensation Policy
2016-05-1210-Q10.1License and Transfer Agreement by and between the Company and Enumeral Biomedical Holdings, Inc dated as of April 18, 2016.
2016-04-2910-K/A10.11Research Collaboration and License Agreement by and among the Registrant, Pieris GmbH, Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd., dated as of December 8, 2015
2016-03-2310-K10.11Research Collaboration and License Agreement by and among the Registrant, Pieris GmbH, Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd., dated as of December 8, 2015

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Generate Biomedicines, Inc. (GENB)United States$2.052B
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12